A recent clinical trial looking at inhaled TLR9 agonist for the treatment of lung cancer reported several adverse events in patients all related to inflammatory immune responses (NCT03326752) (53), suggesting that TLR9 activation while potent may require more targeted delivery strategies that prevent exposure to all tissues. This evidence concerns the gene TLR9 and lung cancer.